News | Catheters | May 10, 2022

WLNC Highlights Q Catheter Compatibility in Simulated Robotic Thrombectomy

The MIVI Neuroscience Q Aspiration Catheter incorporates a novel pusher wire design on its proximal end. This feature has demonstrated in simulated use studies that the Q Catheter may be uniquely suited to allow physicians in the future to treat ischemic stroke patients remotely via a robot from a different room, a different city, or even a different country. 

May 10, 2022 — The MIVI Neuroscience Q Aspiration Catheter incorporates a novel pusher wire design on its proximal end. This feature has demonstrated in simulated use studies that the Q Catheter may be uniquely suited to allow physicians in the future to treat ischemic stroke patients remotely via a robot from a different room, a different city, or even a different country. 

Dr. Demetrius Lopes of Advocate Lutheran General Hospital in Park Ridge, Illinois, has conducted flow-model compatibility testing with the Q catheter and the Corindus GRX robot. Using a simulated neurovascular model, Lopes has been able to show preliminary compatibility between the Q Catheter and the robot system and perform a successful thrombectomy procedure. Lopes will present his experience at the World Live Neurovascular Conference (WLNC) May 11-13 in Washington, D.C.

The Corindus GRX Vascular Robotic system is currently approved for use in endovascular coronary and peripheral therapies, and FDA approval for a neurovascular indication may be on the horizon. The robotic system is designed to be used with rapid exchange angioplasty balloons and balloon-mounted stents, which is the preferred platform in cardiology.

Due to its unique design, the Q Catheter functions with the robot very similarly to these rapid exchange devices. The Q Catheter, currently FDA cleared for use with compatible guide catheters in facilitating the insertion and guidance of microcatheters into a selected blood vessel in the peripheral, coronary and neuro vascular systems, is not currently cleared for thrombectomy but is currently in a clinical study for future market clearance in the U.S.

“Not only does the Q Catheter’s design maximize aspiration force for the best chance at revascularization, it also overcomes the challenge of the robotic system and limitations of traditional catheters” said Lopes. “I was very pleased with the Q Catheter tracking and aspiration performance in this initial testing with the robot.”     

Bob Colloton, CEO of MIVI Neuroscience, commented “As a company, our goal is to meet the unmet needs of our neurovascular physicians with innovative solutions. Regardless of where or how the procedure is performed, we want physicians to be able to choose the Q Catheter because it offers the highest aspiration power and a simple, single-operator setup. We are proud to partner with Dr. Lopes to show that the Q Catheter is well-poised for the future of mechanical thrombectomy.”

Q Catheter for Neurovascular Thrombectomy: CAUTION­­ Investigational device. Limited by United States law to investigational use.

For more information: www.mivineuro.com

Related Robots in the Cath Lab Content:

VIDEO: Robotic PCI Performed Well in Real-World Population in the PRECISION GRX Study — Ehtisham Mahmud, M.D.

Second Generation Robotic PCI System Performs Well Across Spectrum of Lesion Complexity

VIDEO: Standardizing PCI Through Smart Robotic Procedural Automation

Corindus Launches technIQ 1 Smart Procedural Automation Series for CorPath GRX Cath lab Robotic System

FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions

VIDEO: Corindus CorPath Robotic PCI System For The Cardiac Cath Lab

Corindus CorPath Used in World's First-in-Human Telerobotic Coronary Intervention

14 Ways to Reduce Radiation Exposure in the Cath Lab

Corindus Seeking Neurovascular Intervention Clearance for CorPath GRX Vascular Robotic System

Innovations Driving the Cath Lab Technology of Tomorrow

Siemens Completes Acquisition of Cath Lab Robotics Vendor Corindus

First Robotic Coronary Angioplasties Performed With Robocath System in Germany

Hoag Performs First Robotic Carotid Artery Stenting on West Coast


Related Content

News | Thrombectomy Devices

Nov. 5, 2024 —Penumbra, Inc. recently announced new data that demonstrate patients with intermediate-risk pulmonary ...

Home November 07, 2024
Home
News | Thrombectomy Devices

Sept. 24, 2024 — Thrombolytic Science, LLC (TSI) has announced that the U.S. Food and Drug Administration (FDA) has ...

Home September 24, 2024
Home
News | Thrombectomy Devices

Sept. 5, 2024 - Prolocor, Inc. and Slingshot Biosciences recently announced the publication in Bioanalysis of the ...

Home September 10, 2024
Home
News | Thrombectomy Devices

January 16, 2024 — Penumbra, Inc., a thrombectomy company, has recently secured CE Mark (Conformité Européenne) for its ...

Home January 16, 2024
Home
Feature | Thrombectomy Devices | By Global Market Insights

The global thrombectomy devices market is poised to experience substantial expansion, owing to the emergence of ...

Home June 27, 2022
Home
News | Thrombectomy Devices

January 10, 2022 – Akura Medical Inc., a Shifamed portfolio company, announced the closing of its $25 million Series A1 ...

Home January 10, 2022
Home
News | Thrombectomy Devices

November 12, 2021 — Penumbra Inc. announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter ...

Home November 12, 2021
Home
News | Thrombectomy Devices

January 8, 2021 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Inari Medical Inc ...

Home January 08, 2021
Home
News | Thrombectomy Devices

September 25, 2020 — Philips Healthcare launched its QuickClear mechanical thrombectomy system. The compact, single-use ...

Home September 25, 2020
Home
Technology | Thrombectomy Devices

July 25, 2019 — Penumbra announced U.S. commercial availability of the Penumbra System’s most advanced technology, the ...

Home July 25, 2019
Home
Subscribe Now